Page last updated: 2024-12-06

nitrohydroxyiodophenylacetate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Nitrohydroxyiodophenylacetate: Also called 4-hydroxy-3-iodo-5-nitrophenylacetate. A haptenic determinant that can be radiolabeled and used as salts and derivatives for investigations of immunogenic specificity studies. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

(4-hydroxy-3-iodo-5-nitrophenyl)acetic acid : A member of the class of phenylacetic acids that is phenylacetic acid in which the phenyl group is substituted by iodo, hydroxy and nitro groups at positions 3, 4 and 5 respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID17553
CHEBI ID53798
SCHEMBL ID378767
MeSH IDM0014906

Synonyms (22)

Synonym
nitrohydroxyiodophenylacetate
(4-hydroxy-3-iodo-5-nitrophenyl)acetic acid
2-(4-hydroxy-3-iodo-5-nitrophenyl)acetic acid
4-hydroxy-3-iodo-5-nitro-benzeneacetic acid
CHEBI:53798
4-hydroxy-3-iodo-5-nitrobenzeneacetic acid
nip-hapten
nitrohydroxyiodophenylacetic acid
2646-51-7
(4-hydroxy-5-iodo-3-nitrophenyl)acetic acid
benzeneacetic acid, 4-hydroxy-3-iodo-5-nitro-
4-hydroxy-3-iodo-5-nitro-phenylacetic acid
4-hydroxy-3-iodo-5-nitrophenylacetic acid
KPWFDZXSCIFGNO-UHFFFAOYSA-N
SCHEMBL378767
AKOS024374943
DTXSID70181057
nip-oh
J-016443
FT-0751615
4-hydroxy-3-iodo-5-nitro-phenylaceticacid
Q27124217
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
antigenAny substance that stimulates an immune response in the body, such as through antibody production or by presentation to a T-cell receptor after binding to a major histocompability complex (MHC).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
organoiodine compoundAn organoiodine compound is a compound containing at least one carbon-iodine bond.
2-nitrophenolsA mononitrophenol that is 2-nitrophenol and its derivatives resulting from substitution of one or more of the hydrogens attached to the benzene ring by a non-nitro group.
phenylacetic acidsAny monocarboxylic acid that is phenylacetic acid or its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (81)

TimeframeStudies, This Drug (%)All Drugs %
pre-199052 (64.20)18.7374
1990's13 (16.05)18.2507
2000's11 (13.58)29.6817
2010's5 (6.17)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.68

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.68 (24.57)
Research Supply Index4.44 (2.92)
Research Growth Index4.12 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.68)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (3.57%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other81 (96.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]